Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if nab-paclitaxel combined with gemcitabine prevents the
formation or growth of tumors in participants with relapsed or refractory osteosarcoma, Ewing
sarcoma, rhabdomyosarcoma and other soft tissue sarcoma and to measure the length of time
during and after treatment that their disease does not get worse. Researchers also want to
find out if nab-paclitaxel combined with gemcitabine is safe and tolerable.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute